首页> 美国卫生研究院文献>International Journal of Molecular Sciences >In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery
【2h】

In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery

机译:体内评估的丙酸氯倍他索负载的卵磷脂-壳聚糖纳米颗粒的皮肤递送。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this work was to assess in vivo the anti-inflammatory efficacy and tolerability of clobetasol propionate (CP) loaded lecithin/chitosan nanoparticles incorporated into chitosan gel for topical application (CP 0.005%). As a comparison, a commercial cream (CP 0.05% w/w), and a sodium deoxycholate gel (CP 0.05% w/w) were also evaluated. Lecithin/chitosan nanoparticles were prepared by self-assembling of the components obtained by direct injection of soybean lecithin alcoholic solution containing CP into chitosan aqueous solution. Nanoparticles obtained had a particle size around 250 nm, narrow distribution (polydispersity index below 0.2) and positive surface charge, provided by a superficial layer of the cationic polymer. The nanoparticle suspension was then loaded into a chitosan gel, to obtain a final CP concentration of 0.005%. The anti-inflammatory activity was evaluated using carrageenan-induced hind paw edema test on Wistar rats, the effect of formulations on the barrier property of the stratum corneum were determined using transepidermal water loss measurements (TEWL) and histological analysis was performed to evaluate the possible presence of morphological changes. The results obtained indicate that nanoparticle-in-gel formulation produced significantly higher edema inhibition compared to other formulations tested, although it contained ten times less CP. TEWL measurements also revealed that all formulations have no significant disturbance on the barrier function of skin. Furthermore, histological analysis of rat abdominal skin did not show morphological tissue changes nor cell infiltration signs after application of the formulations. Taken together, the present data show that the use of lecithin/chitosan nanoparticles in chitosan gel as a drug carrier significantly improves the risk-benefit ratio as compared with sodium-deoxycholate gel and commercial cream formulations of CP.
机译:这项工作的目的是在体内评估掺入壳聚糖凝胶中局部应用的丙酸氯倍他索(CP)的卵磷脂/壳聚糖纳米粒子的抗炎功效和耐受性(CP 0.005%)。作为比较,还评估了市售乳膏(CP 0.05%w / w)和脱氧胆酸钠凝胶(CP 0.05%w / w)。卵磷脂/壳聚糖纳米颗粒通过将含有CP的大豆卵磷脂醇溶液直接注入壳聚糖水溶液中而获得的组分进行自组装而制备。得到的纳米颗粒具有约250nm的粒径,窄分布(多分散指数低于0.2)和由阳离子聚合物的表面层提供的正表面电荷。然后将纳米颗粒悬浮液加载到壳聚糖凝胶中,以获得0.005%的最终CP浓度。使用角叉菜胶诱导的后足水肿试验评估Wistar大鼠的抗炎活性,使用经皮表皮失水量测定(TEWL)确定制剂对角质层屏障特性的影响,并进行组织学分析以评估可能的作用。形态变化的存在。获得的结果表明,与其他测试的制剂相比,纳米凝胶凝胶制剂产生的水肿抑制作用明显更高,尽管它的CP含量要少十倍。 TEWL的测量结果还表明,所有制剂对皮肤的屏障功能均无明显影响。此外,对大鼠腹部皮肤的组织学分析未显示出在施用制剂后的形态组织变化或细胞浸润迹象。两者合计,本数据表明,与CP的脱氧胆酸钠凝胶和市售乳膏制剂相比,在壳聚糖凝胶中使用卵磷脂/壳聚糖纳米颗粒作为药物载体显着提高了风险收益比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号